Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11329020 | 0.82 | S1PR1 (0.35) | S1PR1 | |
| SCHEMBL12299809 | 0.82 | MAPT (0.42) | CTSK | |
| SCHEMBL19245762 | 0.82 | S1PR1 (0.33) | S1PR1 | |
| SCHEMBL18460622 | 0.82 | S1PR1 (0.33) | S1PR1 | |
| SCHEMBL25017779 | 0.81 | GRIN1 (0.30) | GRIN1GRIN2B | |
| SCHEMBL11325095 | 0.79 | ALDH1A1 (0.42) | GRIN1GRIN2B | |
| SCHEMBL13856441 | 0.79 | NOTUM (0.42) | CTSK | |
| SCHEMBL22600415 | 0.79 | NOTUM (0.42) | GRIN1GRIN2B | |
| SCHEMBL19229031 | 0.79 | BRD4 (0.30) | — | |
| SCHEMBL7602053 | 0.79 | ELANE (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024105104-A1 | MICROBIOCIDAL TETRAHYDROISOQUINOLINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024026500-A2 | INHIBITORS OF PDE11A4 AND METHODS OF USING SAME | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023227757-A1 | QUINONE PROTECTED FORMS AND CONJUGATES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-11-30 | — | — | WO | disclosed |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-4248975-A2 | RIP1 INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME | Rigel Pharmaceuticals, Inc. (US) | 2023-09-27 | — | — | EP | disclosed |
| WO-2023177356-A2 | COMPOUNDS AND METHOD FOR PKMYT1 INHIBITION | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-09-21 | — | — | WO | disclosed |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | Arrowhead Pharmaceuticals, Inc. | 2023-08-24 | — | — | US | disclosed |
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | DANA-FARBER CANCER INSTITUTE, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230123569-A1 | COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2023-04-20 | — | — | US | disclosed |
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-02-23 | — | — | US | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| WO-2007117381-A9 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC (US) | 2008-03-27 | — | — | WO | disclosed |
| WO-2007117381-A2 | 2 -AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-20070197628-A1 | Cannabinoid receptor modulators | INTERVET INTERNATIONAL B.V. (NL) | 2007-08-23 | — | — | US | disclosed |
| US-20070191433-A1 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MERCK SHARP & DOHME CORP. | 2007-08-16 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006002099-A2 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | S1PR1 414/4885CTSK 567/4885GRIN1 4665/4885 |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | S1PR1 414/4885CTSK 567/4885GRIN1 4665/4885 |
| US-20230058950-A1 | UREA COMPOUND HAVING SUBSTITUENT | SIRT6, SIRT1, SIRT2 | S1PR1 1538/4885CTSK 3626/4885GRIN1 3834/4885 |
| US-20230265082-A1 | SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 | USP28, USP1, USP18 | S1PR1 4154/4885CTSK 1583/4885GRIN1 2622/4885 |
| US-20230123569-A1 | COMPOUNDS AS AUTOTAXIN INHIBITORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | ENPP2, PLA2G10, LPCAT1 | S1PR1 170/4885CTSK 229/4885GRIN1 3601/4885 |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | PI4KA, IP6K3, PHOSPHO1 | S1PR1 63/4885CTSK 2760/4885GRIN1 3254/4885 |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | S1PR1 3358/4885CTSK 2675/4885GRIN1 3252/4885 |
| US-20070197628-A1 | Cannabinoid receptor modulators | CNR1, CNR2, GPR18 | S1PR1 150/4885CTSK 4223/4885GRIN1 141/4885 |
| US-20230265429-A1 | SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF | MUSK, MYLK2, TNNC1 | S1PR1 1060/4885CTSK 2132/4885GRIN1 4703/4885 |
| US-20070191433-A1 | Acylated piperidine derivatives as melanocortin 4-receptor agonists | MC4R, MC5R, MC3R | S1PR1 1076/4885CTSK 3275/4885GRIN1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.